6-硝基吲唑钠 | 104436-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-硝基吲唑钠
• 英文名称: sodium 6-nitroindazolide
• 英文别名: sodium;6-nitroindazol-2-ide
• CAS: 104436-77-3
• 化学式: C₇H₄N₃O₂*Na
• 分子量: 185.117
• InChiKey: HXZFFGKRWUJORS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-硝基吲唑钠 在 氢气 、 溶剂黄146 、 乙酸乙酯 作用下， 以 丙酮 为溶剂， 反应 78.0h， 生成 methyl 4-<(6-aminoindazol-1-yl)methyl>benzoate
  参考文献：
  名称：

  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles

  摘要：

  A perception of structural similarities between two independent series of leukotriene antagonists (one emanating from FPL 55712 and one based upon the leukotrienes themselves) led to the discovery of a novel class of indole and indazole derived antagonists of peptidoleukotrienes. A systematic exploration of C-6 substituted 4-(indol-1-ylmethyl)-3-methoxybenzoic acids identified cyclopentylacetamide and cyclopentylurethane as preferred substituents. The corresponding indazoles were equipotent. These compounds are selective leukotriene antagonists with pKB values of 7.5-7.8 vs LTE4 on guinea pig trachea.

  DOI：

  10.1021/jm00168a036

文献信息

• A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles
  作者：Ying K. Yee、Peter R. Bernstein、Edward J. Adams、Frederick J. Brown、Laura A. Cronk、Kevin C. Hebbel、Edward P. Vacek、Robert D. Krell、David W. Snyder

  DOI：10.1021/jm00171a018

  日期：1990.9

  A systematic structure-activity exploration of the carboxylic acid region in a series of indole- or indazole-derived leukotriene antagonists 1 led to several discoveries. Use of the 3-methoxy-p-tolyl fragment (illustrated in acid 1) for connecting the indole and the acidic site provides the most potent carboxylic acids 1, tetrazoles 20, and aryl sulfonimides 21. The aryl sulfonimides are 5-500 times

  对一系列由吲哚或吲唑衍生的白三烯拮抗剂1的羧酸区域进行系统的结构活性探索导致了一些发现。使用3-甲氧基对甲苯基片段（如酸1中所示）连接吲哚和酸性位点可提供最有效的羧酸1，四唑20和芳基磺酰亚胺21。芳基磺酰亚胺的含量是5-500倍以上（在体外和/或体内）比相应的羧酸更有效。在给定的体外活性水平下，邻甲苯基磺酰亚胺（如114）显示出比苯基磺酰亚胺更大的口服效力。酸性酮砜衍生物10（Nu = CH-（CO2CH3）SO2Ph）模拟了磺酰亚胺的活性。
• Indazole compounds, pharmaceutical compositions and use
  申请人：ICI Americas Inc.

  公开号：US04997844A1

  公开（公告）日：1991-03-05

  The invention provides a series of novel heterocyclic amides of the formula I in which the group A CRa can be --CRb.dbd.CRa--, --CHRb--CHRa-- or --N.dbd.CRa--, the amidic group Re.L can be Re.X.CO.NH, Re.X.CS.NH or Re.NH.CO attached at position 4, 5 or 6 of the benzenoid moiety, Z is an acid group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula CO.NH.SO.sub.n Rg and a tetrazolyl residue of the formula II, and the radicals Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, n, X, G.sup.1, Q and G.sup.2 have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compounds, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.

  该发明提供了一系列新颖的杂环酰胺，其化学式为I，在该化学式中，基团A CRa可以是--CRb.dbd.CRa--，--CHRb--CHRa--或--N.dbd.CRa--，酰胺基团Re.L可以是连接在苯环部分的第4、5或6位的Re.X.CO.NH，Re.X.CS.NH或Re.NH.CO，Z是从羧基、公式CO.NH.SO.sub.n Rg的酰磺胺残基或公式II的四唑基残基中选择的酸基团，基团Ra、Rb、Rc、Rd、Re、Rf、Rg、Rh、n、X、G.sup.1、Q和G.sup.2的含义在以下说明中定义。化合物I的化学式是白三烯拮抗剂。该发明还提供了化合物I的药学上可接受的盐；含有化合物I或其盐的药物组合物，用于治疗过敏性或炎症性疾病、内毒素性休克或创伤性休克等疾病；以及用于制造化合物I的方法，以及用于该制造的中间体。
• SEARCEY, MARK;LEE, JOHN B.;PYE, PETER L., CHEM. AND IND.,(1989) N7, C. 569-570
  作者：SEARCEY, MARK、LEE, JOHN B.、PYE, PETER L.

  DOI：——

  日期：——
• BROWN, FREDERICK J.;YEE, YING K.;CRONK, LAURA A.;HEBBEL, KEVIN C.;KRELL, +, J. MED. CHEM., 33,(1990) N, C. 1771-1781
  作者：BROWN, FREDERICK J.、YEE, YING K.、CRONK, LAURA A.、HEBBEL, KEVIN C.、KRELL, +

  DOI：——

  日期：——
• Heterocyclic amides
  申请人：ICI AMERICAS INC.

  公开号：EP0179619B1

  公开（公告）日：1990-09-05